If you have any question, please feel free to email us. We will touch with you as soon as possible.
CAS:52232-67-4
Source:Europe
Qualifications:-/-/-/-/-
| Name | Teriparatide Acetate |
|---|---|
| Chinese name | 醋酸特立帕肽 |
| Cas Number | 52232-67-4 |
| Source | Europe |
| Qualifications | -/-/-/-/- |
Teriparatide is the first new bone forming agent approved by the Food and Drug Administration. This parathyroid hormone derivative can promote bone growth by increasing the activity and number of osteoblasts. The conventional osteoporosis drugs generally only act on osteoclasts to slow or block bone loss. Compared with those who only took calcium and vitamin D supplements, 96% of patients received this drug treatment, The bone (mineral) density BMD of the spine and hip showed a significant increase. In addition, it was found that the drug can reduce the risk of spinal fractures and other types of fractures by 65% and 53%, respectively. In 2019, teriparatide's global sales were approximately US$1.4 billion.
Hot Tags: teriparatide acetate api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Clofarabine API, Edoxaban API, Lercanidipine Hydrochloride API, Oseltamivir Phosphate API, Adapalene API, Teriflunomide API
Tel:+86-020-61855200-902
Fax:+86-020-66392525
Email:info@upharm.cn
Address:12th floor, No. 181, Kexue Avenue, Huangpu District, Guangzhou, China
